> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CVS Health beats and raises, stock falls on 2027 headwinds
- URL: https://members.americanhealthintel.com/2026-08-05-ledger/
- Published: 2026-08-05T18:26:53.000Z
- Updated: 2026-08-05T18:26:53.000Z
- Description: Plus: Eli Lilly Q2 revenue hits $23B on Mounjaro, Zepbound growth. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: Eli Lilly Q2 revenue hits $23B on Mounjaro, Zepbound growth. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Wednesday, August 5, 2026 CVS Health beats and raises, stock falls on 2027 headwinds Plus: Eli Lilly Q2 revenue hits $23B on Mounjaro, Zepbound growth. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Record CVS Health, the company behind Aetna and the CVS pharmacy chain, beat Wall Street on revenue and earnings this morning and raised its full-year guidance, and its stock fell more than 6 percent anyway. Aetna's medical costs finally cooled, but executives flagged 2027 headwinds in a federal drug-discount program and expected membership losses at its pharmacy benefit manager. CVS also cut virtual weight-loss visits to $29 the same day. Record Eli Lilly, the drugmaker behind diabetes and weight-loss shots Mounjaro and Zepbound, posted 23 billion dollars in quarterly revenue, up 48 percent, and raised its full-year guidance for the second time this year. Mounjaro alone brought in 9.9 billion dollars, up 91 percent. The results landed the same day CVS Health restored Lilly's weight-loss drugs to preferred insurance coverage, a win over rival Novo Nordisk. Also today Novo Nordisk raises outlook, shares fall on pill miss and failed trial [Read](https://americanhealthintel.com/editions/2026-08-05-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#novo-nordisk-q2-2026-wegovy-pill-miss-trial-failure) FRONTIER SCAN: Henry Ford and Intermountain price $2.4B in bonds [Read](https://americanhealthintel.com/editions/2026-08-05-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#henry-ford-intermountain-health-muni-bond-pricing-frontier-scan) CareCloud data breach hits 345,000 patients [Read](https://americanhealthintel.com/editions/2026-08-05-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#carecloud-345000-patient-data-breach) 374Records$31.6BEnforcement17Deadlines110Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-05-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |